Clindamycin Phosphate Injection shortage
Current 23 presentations · 4 manufacturers · first FDA posting 2023-03-21 · last update 2026-10-08
Manufacturers: Baxter Healthcare, Pfizer Inc., Sagent Pharmaceuticals, Sandoz Inc.
Stated reasons (per FDA): Demand increase for the drug; Discontinuation of the manufacture of the drug
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50) | Baxter Healthcare | Current Available |
— | Posted 03/21/2023 Updated 10/02/2026 | |
| Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50) | Baxter Healthcare | Current Unavailable |
Demand increase for the drug | Estimated recovery: October 2026 | Posted 03/21/2023 Updated 10/02/2026 |
| Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50) | Baxter Healthcare | Current Unavailable |
Demand increase for the drug | Estimated recovery: November 2026 | Posted 03/21/2023 Updated 10/02/2026 |
| Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50) | Baxter Healthcare | Current Available |
— | Posted 03/21/2023 Updated 10/02/2026 | |
| Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50) | Baxter Healthcare | Current Available |
— | Posted 03/21/2023 Updated 10/02/2026 | |
| Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50) | Baxter Healthcare | Current Available |
— | Posted 03/21/2023 Updated 10/02/2026 | |
| Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26) | Pfizer Inc. | Current Available |
— | Posted 03/21/2023 Updated 09/21/2026 | |
| Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26) | Pfizer Inc. | Current Unavailable |
Demand increase for the drug | Next Delivery and Estimated Recovery: December 2028 | Posted 03/21/2023 Updated 09/21/2026 |
| Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18) | Pfizer Inc. | Current Available |
— | Posted 03/21/2023 Updated 09/21/2026 | |
| Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02) | Sagent Pharmaceuticals | Current Limited Availability |
Discontinuation of the manufacture of the drug | Selling through remaining short-dated inventory (Dec 2026). | Posted 03/21/2023 Updated 10/08/2026 |
| Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04) | Sagent Pharmaceuticals | Current Unavailable |
Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Posted 03/21/2023 Updated 10/08/2026 |
| Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06) | Sagent Pharmaceuticals | Current Limited Availability |
Discontinuation of the manufacture of the drug | Selling through remaining short-dated inventory (Dec 2026). | Posted 03/21/2023 Updated 10/08/2026 |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09) | Sandoz Inc. | Current Available |
— | Posted 03/21/2023 Updated 10/08/2026 | |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09) | Sandoz Inc. | Current Available |
— | Posted 03/21/2023 Updated 10/08/2026 | |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09) | Sandoz Inc. | Current Available |
— | Posted 03/21/2023 Updated 10/08/2026 | |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24) | Sandoz Inc. | Current Available |
— | Civica Label | Posted 03/21/2023 Updated 10/08/2026 |
| Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24) | Sandoz Inc. | Current Available |
— | Civica Label | Posted 03/21/2023 Updated 10/08/2026 |
| Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 06/01/2026 Updated 06/01/2026 Discontinued 06/01/2026 |
| Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 06/01/2026 Updated 06/01/2026 Discontinued 06/01/2026 |
| Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 06/01/2026 Updated 06/01/2026 Discontinued 06/01/2026 |
| Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 06/01/2026 Updated 06/01/2026 Discontinued 06/01/2026 |
| Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 06/01/2026 Updated 06/01/2026 Discontinued 06/01/2026 |
| Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 06/01/2026 Updated 06/01/2026 Discontinued 06/01/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)